New for 2013: Free online updates for a year
Get instant, interactive pathway modeling on almost 3,000 cancer drugs across
close to 90 different cancer types.
Drug targets and their pathways are the critical link between drugs and their
role in the treatment of cancer. This highly unique interactive tool is based
on BioSeeker's linking of hundreds of drug targets in many different types of
cancer to a wide array of pathways. The included drugs are all from early
stage development to market in maturity; also featuring ceased and suspended
The Oncology Drug Pathway Analyzer is an interactive high level data tool to
analyze several thousand drug-pathway connections in close to 90 different
cancer indications on the fly. The tool lets you examine both single pathways
and crosstalk between pathways of drugs and filter the included drugs per
pathway by twelve drug specific parameters (i.e. Indication, Stage, Company,
Molecular function etc.).
The Oncology Drug Pathway Analyzer is a great facilitator to realize your
position and options in drug development when utilizing pathways and it
significantly cuts the amount of time it takes to do so.
Read more below on how to bring out the power in your pipeline and start to
quickly analyze the impact of emerging pathway data in cancer by getting your
own version of the Oncology Drug Pathway Analyzer.
Why you should use this tool:
- Map the competition and find suitable benchmarking drugs based on specific
pathways and drug properties
- Reveal repositioning opportunities for your older, shelved drugs
- Evaluate the progression and success of targeting certain pathways for the
treatment of cancer
- Investigate drugs which affect crosstalk between key pathways
- Investigate different combination therapy options available to you in
various cancer types. Use this tool to look for the most-efficient ways to
combine your drug with other targeted agents.
- Find possible adjuvant therapy settings with other drugs
Real case scenario (combination therapy):
In the March 20, 2012 issue of the journal Cancer Cell, researchers at The
University of Texas MD Anderson Cancer Center reveal that the mTOR molecular
pathway stimulates the activity of the Gli1 protein in the development and
progression of esophageal cancer. Hitherto it is known that the Hedgehog
pathway is the established pathway for activating Gli1. In experiments the
researchers then went on to show that a combination of the mTOR inhibitor
everolimus (Afinitor) and the Hedgehog inhibitor vismodegib (Erivedge) steeply
reduced the tumor burden in a mouse model of esophageal adenocarcinoma.
Our tool would in seconds let you know how many and which drug are available
for potential drug combination therapies in affecting both the Hedgehog- and
the mTOR pathway. It also would instantly tell you which drugs is available
affecting both pathways. You could then further refine the results by up to
eleven drug specific parameters (i.e. Indication, Stage, Company, Molecular
function etc.). There after you can view in-depth progress reports on each of
the drugs of interest to you (Premium version). The Oncology Drug Pathway
Analyzer comes in two versions, Standard and Premium. The additional great
feature of the Premium version is that it also gives you instant access to
almost 3,000 up to date and extensive drug developmental profiles (at the low
price of around 1 EUR/profile).
Oncology Drug Pathway Analyzer (Premium Version) published by BioSeeker Group AB in January 14, 2013. This report price starts from US $ 14850.
The contents of this page may be different from the latest version. Please contact us for details.